Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium dificile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its microbiom... More

Recent NewsMore
11/10/16
Seres Therapeutics Reports Third Quarter 2016 Financial Results and Provides Operational Progress Update
- Analyses of SER-109 Phase 2 results on track for completion by year end; Company intends to discuss proposed future SER-109 clinical development plans with the FDA - - Pipeline progress with SER-287 and SER-262 Phase 1b study execution; data read-outs continue to be expected in 2017 - - New microbiome patent strengthens the Company’s intellectual property estate - - Conference call at 8:00 a.m. ET today - ... 
11/04/16
Seres Therapeutics to Host Third Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Thursday, November 10, 2016 at 8:00 a.m. ET to discuss third quarter 2016 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (internatio... 
08/11/16
Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Progress Update
- Comprehensive review of initial SER-109 Phase 2 study data underway - - Strong cash position to support operations well into 2018, and through the anticipated Phase 1b study read-outs for SER-287 and SER-262 – - Conference call at 8:30 AM ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 11, 2016-- Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today reported second quarter... 
EventsMore
There are currently no upcoming events scheduled.
Stock Quote
NASDAQ:MCRB
$10.32
 + 0.38 (3.82%)
12/02/16 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.